MI-EATON
6.9.2022 12:31:56 CEST | Business Wire | Press release
Power management company Eaton will display its Vehicle Group's innovative portfolio of internal combustion solutions for commercial vehicles Sept. 20-25 at the IAA Transportation show in Hannover, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005013/en/
Eaton’s Vehicle Group offers a portfolio of technologies that reduce emissions and improve fuel economy in commercial vehicles today and well into the future. (Photo: Business Wire)
"Although the transition to electrification is progressing, OEMs continue to seek improvements in fuel emissions and consumption for internal combustion engines," said Traci Melville, senior vice president and general manager, Global Products, Eaton's Vehicle Group. "In fact, according to KGP Powertrain Intelligence, there will be more than 30 million commercial vehicles produced with a diesel engine over the next decade."
Variable Valve Actuation technologies are flexible, reduce emissions
Eaton's Variable Valve Actuation (VVA) solutions are flexible and adaptable to any valvetrain architecture, allowing OEM customers to implement one or multiple functions that can significantly reduce carbon dioxide (CO2) and nitrogen oxides (NOx) emissions and lower fuel use.
Cylinder deactivation keeps selective catalytic reduction (SCR) at optimal temperatures by operating just two or three cylinders rather than all six in light-load conditions. That effectively delivers higher exhaust temperatures from the functioning cylinders at low speeds and loads or when the truck is neutral coasting, two conditions that can quickly cool aftertreatment systems. Concurrently, cylinder deactivation also lowers fuel consumption.
Late intake valve closing improves the engine's thermal efficiency, enabling a higher compression ratio, which reduces CO2 emissions and increases exhaust gas temperature that contributes to aftertreatment performance.
TVS EGR pump more controllable than competitive offerings
Eaton's positive-displacement TVS® exhaust gas recirculation (EGR) pump enables the use of a high-efficiency turbo to reduce engine pumping losses and increase fuel economy. The TVS® EGR pump is driven by a 48-volt electric motor, making it completely independent from engine speed and significantly more controllable than pumpless EGR systems.
Decompression engine brake compact, integrates into small engines
Eaton's decompression engine brake technology enhances brake power in the full engine operating range and is compact for easy integration into smaller engines.
Eaton's engine decompression brake is a valvetrain system with a mechanism to quickly switch between driving and engine braking mode according to customer requirements and can be integrated into a standard assembly.
Eaton's valves operate in demanding engine applications
Eaton offers a portfolio of differing valves, including monometallic and bimetallic, solid and hollow sodium cooled, seat faced and coated, providing a suitable solution for all vehicle applications. Eaton is developing new valve technologies for future commercial vehicles, including those with hydrogen internal combustion engines (ICE). Unlike traditional diesel-powered commercial vehicle engines, hydrogen ICE powertrains can operate dry combustion at extremely elevated temperatures depending on engine calibration.
Eaton is leveraging its nearly 100 years of experience in valve production to support hydrogen applications and the next generation of diesel engines. One possible solution is a sodium-filled hollow valve, which enables internal cooling. Wear protection is ensured by selecting the proper materials and coatings among the several grades available in Eaton's portfolio.
Eaton, Tenneco offer exhaust thermal management system to reduce emissions
Eaton and Tenneco launched a joint development agreement between Eaton's Vehicle Group and Tenneco's Clean Air business to produce an integrated exhaust thermal management system that enables commercial truck manufacturers to meet upcoming emissions regulations.
The integrated exhaust thermal management system provides heat directly to the vehicle's aftertreatment system, which is essential for reducing harmful exhaust emissions. Eaton's electrically driven TVS® blower precisely controls the airflow so the system can maintain optimal aftertreatment temperatures.
48-volt electric catalyst heater controller provides precise aftertreatment control
Eaton offers an air-cooled electric catalyst heater controller as part of its broader 48-volt electrical system portfolio. It contains several technologies that allow manufacturers to integrate 48-volt architectures into next-generation commercial vehicles. The controller manages the power delivered to the aftertreatment heater and is designed to receive commands from the aftertreatment system and provide soft-start and soft-stop capabilities for maintaining system voltage control.
48-volt DC-DC Converter for dual-voltage electrical systems
Eaton is developing a DC-DC Converter for 48V system architectures that will enable future powertrains to comply with new emissions regulations and provide higher levels of electrical power for CO2 reduction and autonomous driving systems. Unlike competitive offerings, Eaton's DC-DC converters are operational in ambient temperatures up to 85 degrees Celsius and boast 97% design efficiency.
Supercapacitors for 48-volt system power storage
Eaton has a current portfolio of supercapacitors for use in commercial vehicle applications, including 48V commercial vehicle systems. In addition, Eaton is developing advanced technology to further increase the level of power and energy storage capacity in these products.
Supercapacitors can quickly charge and discharge at higher rates than lithium-ion batteries. While the size and weight are comparable to lithium-ion packs, supercapacitors don't retain high levels of energy in comparison, do not require a liquid cooling system and have a longer cycle life.
Eaton is an intelligent power management company dedicated to improving the quality of life and protecting the environment for people everywhere. Eaton is guided by its commitment to do business right, to operate sustainably and to help its customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, Eaton is accelerating the planet's transition to renewable energy, helping to solve the world's most urgent power management challenges, and doing what's best for its stakeholders and all of society.
Founded in 1911, Eaton has been listed on the NYSE for nearly a century. We reported revenues of $19.6 billion in 2021 and serve customers in more than 170 countries. For more information, visit www.eaton.com. Follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005013/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
